ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

Reagan Signs 12989 Appropriations Bill; Reauthorization Still Held Up In Congress

September 23, 1988

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

December 17, 2013

Physician Clinical Investigator Awards

April 15, 1983

DCCR Plans Three Multiple Contracts In Pain Control

February 17, 1978

Fogarty Leads Grant Program On World Tobacco Research.

July 6, 2001

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

August 8, 1980